Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 160 participants.
Also called NCT05580510
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 160 participants
- Registry
-
NCT05580510
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Mexico
- Registry status
- Unknown status
Technical summary
Registry record NCT05580510. Randomized; no masking; primary purpose treatment. Start 2023-02-06 (anticipated); primary completion 2023-07-28 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "
- Condition
- Congenital Heart Disease
- Condition
- Heart Failure
- Intervention (Drug)
- Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID
- Intervention (Drug)
- Empagliflozin 10 MG OD
- Lead sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
- Collaborator
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct05580510- Content hash
61c65dadc8662500c043dad48ea34f23dd8dab65f8f13ef64f787529e3450b22